KR20120054297A - Oral composition containing extract of sapindus mukurossi gaertn - Google Patents

Oral composition containing extract of sapindus mukurossi gaertn Download PDF

Info

Publication number
KR20120054297A
KR20120054297A KR1020100115608A KR20100115608A KR20120054297A KR 20120054297 A KR20120054297 A KR 20120054297A KR 1020100115608 A KR1020100115608 A KR 1020100115608A KR 20100115608 A KR20100115608 A KR 20100115608A KR 20120054297 A KR20120054297 A KR 20120054297A
Authority
KR
South Korea
Prior art keywords
composition
extract
patient
oral cavity
oral
Prior art date
Application number
KR1020100115608A
Other languages
Korean (ko)
Other versions
KR101756306B1 (en
Inventor
채상균
김찬호
이병렬
성영은
이존환
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to KR1020100115608A priority Critical patent/KR101756306B1/en
Publication of KR20120054297A publication Critical patent/KR20120054297A/en
Application granted granted Critical
Publication of KR101756306B1 publication Critical patent/KR101756306B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/77Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A61Q11/02Preparations for deodorising, bleaching or disinfecting dentures

Abstract

PURPOSE: An oral composition containing sapindus mukurossi Gaertn extract is provided to prevent periodontal diseases and to remove bad breath. CONSTITUTION: An oral composition contains 0.0001-20 wt% of sapindus mukurossi Gaertn extract as an active ingredient. The composition further contains 30-60 wt% of sorbitol liquid and 1.0-3.0 wt% of carboxymethyl cellulose. The composition is used for preventing periodontal diseases or removing bad breath.

Description

무환자 추출물을 함유하는 구강용 조성물 {Oral composition containing extract of sapindus mukurossi Gaertn}Oral composition containing extract of sapindus mukurossi Gaertn

본 발명은 무환자 추출물을 함유하는 구강용 조성물에 관한 것으로, 보다 상세하게는 항균력이 뛰어난 무환자 추출물을 함유하고 미세기포로 무환자 추출물을 치아 구석 미세한 부분까지 전달해 주어 잇몸 질환 예방 효과 및 구취 제거 효능이 우수한 구강용 조성물에 관한 것이다.
The present invention relates to a composition for oral cavity containing a patient-free extract, more specifically, containing a patient-free extract with excellent antimicrobial activity, and delivers the patient-free extract as a microbubble to the corners of the teeth to excellent gum disease prevention and bad breath removal effect It relates to a composition for.

일반적으로 잇몸질환을 예방하기 위하여 고안된 구강용 조성물에는 염화나트륨, 알란토인클로로히드록시 알루미늄, 아미노카프론산, 초산토코페롤 등 합성원료들이 그 주를 이루고 있었다. 그러나, 최근 자연 추출물에 대한 관심이 높아지면서 각종 식물에 대한 연구가 활발히 진행되고 있으며, 구강에의 효과들이 알려지면서 많은 추출물들이 잇몸질환예방 및 구취 억제와 관련된 구강 조성물에 응용되고 있다.In general, oral compositions designed to prevent gum disease were composed mainly of synthetic raw materials such as sodium chloride, allantoin chlorohydroxy aluminum, aminocaproic acid, tocopherol acetate. However, as interest in natural extracts has recently increased, studies on various plants have been actively conducted, and as the effects on oral cavity are known, many extracts have been applied to oral compositions related to gum disease prevention and bad breath control.

국내공개특허 제2003-0000275호는 녹차추출물에 의한 치약 제조방법에 관한 것으로서, 상기 녹차추출물은 주 성분인 카테킨 성분의 높은 항균력으로 인한 항균작용 및 항 충치의 기능이 뛰어나고, 또한 입안의 입냄새를 제거하는데 효과가 탁월하여 구취제로서의 역할이 뛰어나다는 사실이 개시되어 있다.Korean Laid-Open Patent No. 2003-0000275 relates to a toothpaste manufacturing method using green tea extract, wherein the green tea extract has excellent antibacterial action and anti-cavity function due to high antibacterial activity of the catechin component, which is a main ingredient, and also has a bad breath in the mouth. It is disclosed that the effect as an odorant is excellent because it is excellent in removing.

국내공개특허 제2002-0087672호는 정향 추출물을 함유하고 있어 입안 가글시 청량감을 제공할 뿐만 아니라 항균활성으로 인한 구취제거 및 잇몸질환을 예방하는데 뛰어난 효과가 있고 기존의 청정제가 지니지 못한 진통효과를 가지고 있다는 사실이 개시되어 있다.Korean Laid-Open Patent No. 2002-0087672 contains a clove extract, which not only provides a refreshing feeling in the mouth, but also has an excellent effect in preventing bad breath and gum disease due to antibacterial activity, and has an analgesic effect that conventional cleaning agents do not have. It is disclosed that there is.

국내공개특허 제2002-0066042호는 석류추출물을 함유한 구강 위생 증진용 조성물에 관한 것으로서, 석류 추출물이 활성산소와 산화질소 생성을 억제시키는 작용이 우수함을 확인하여 이러한 항산화 효능을 통하여 구강위생을 증진시키는데 역할이 뛰어나다는 사실이 개시되어 있다.Korean Laid-Open Patent No. 2002-0066042 relates to a composition for promoting oral hygiene containing a pomegranate extract, and confirmed that pomegranate extract has an excellent effect of inhibiting the generation of free radicals and nitric oxide, thereby promoting oral hygiene through such antioxidant effects. It is disclosed that the role is excellent.

국내공개특허 제2001-0036152호는 식물추출물 파우더의 제조 방법 및 이 방법에 의해 제조된 식물추출물 파우더를 함유하는 구강용 조성물에 관한 것으로서, 인공적인 항생제, 살균제보다 민간에서 널리 알려져 온 약용 식물 추출물, 특히 솔잎을 사용하여 구강 내에서 우수한 치주질환 및 충치예방효과를 제공할 수 있다고 개시되어 있다.Korean Laid-Open Patent No. 2001-0036152 relates to a method for producing a plant extract powder and a composition for oral cavity containing the plant extract powder prepared by the method, which is a medicinal plant extract that is more widely known in folks than artificial antibiotics and fungicides, In particular, it is disclosed that the use of pine needles can provide excellent periodontal disease and caries prevention effect in the oral cavity.

상기에서 살펴본 바와 같이, 많은 식물추출물들이 구강위생의 증진목적으로 배합되어 사용되어 오고 있으나, 대개의 경우 빈약한 항균 효과를 가지거나 단순히 소염, 수렴, 지혈, 혈액순환 촉진과 같은 추상적인 효능을 통하여 치주질환의 발생을 예방한다는 정도만을 나타내고 있으며, 안정도 면에서 미흡한 단점이 있어 구강용 조성물로 사용하는데 어려움이 있었다.
As discussed above, many plant extracts have been used for the purpose of promoting oral hygiene, but in most cases have poor antimicrobial effects or simply through abstract efficacy such as anti-inflammatory, convergence, hemostasis, and blood circulation. It only shows the degree of preventing the occurrence of periodontal disease, there is a disadvantage in terms of stability was difficult to use as a composition for oral cavity.

이에, 이에 본 발명자들은 잇몸질환 예방 및 구취 제거를 위해서 여러 식물추출물을 조사하여 분석한 결과, 항균력이 뛰어난 무환자 추출물을 미세 기포를 통해 치아 구석 미세한 곳까지 전달해 주면 잇몸 질환 예방 및 구취 제거 효능이 우수함을 발견하고 본 발명을 완성하였다.Therefore, the present inventors investigated and analyzed various plant extracts for the prevention of gum disease and elimination of bad breath, and when the disease-free extract with excellent antimicrobial power is delivered to the corners of the teeth through microbubbles, it is excellent in preventing gum disease and removing bad breath. And the present invention was completed.

따라서, 본 발명의 목적은 구강용 조성물 내에서 안정하면서 우수한 잇몸질환 예방 및 구취 제거 효과를 나타내는 구강용 조성물을 제공하는 것이다.
Accordingly, it is an object of the present invention to provide a composition for oral cavity which exhibits excellent gum disease prevention and bad breath removal effect while being stable in the composition for oral cavity.

상기 목적을 달성하기 위하여, 본 발명에서는 무환자 추출물을 유효성분으로 함유하는 구강용 조성물을 제공한다.
In order to achieve the above object, the present invention provides a composition for oral cavity containing the patient-free extract as an active ingredient.

본 발명에 따른 구강용 조성물은 항균력이 뛰어난 무환자 추출물을 미세 기포로 치아 구석까지 전달함으로써 타액 내 세균 수를 감소시키며 치은염 및 치주염 등의 잇몸 질환을 효과적으로 예방할 수 있고, 구취 농도 지수를 낮춰 구취 억제 효과가 우수하였다.
The composition for oral cavity according to the present invention reduces the number of bacteria in saliva and effectively prevents gum disease such as gingivitis and periodontitis by delivering the patient-free extract having excellent antimicrobial power to the corners of the teeth with fine bubbles, and lowers the bad breath concentration index. Was excellent.

본 발명은 무환자(sapindus mukurossi Gaertn) 추출물을 유효성분으로 함유하는 구강용 조성물을 제공한다.The present invention provides a composition for oral cavity containing sapindus mukurossi Gaertn extract as an active ingredient.

이하, 본 발명을 보다 상세히 설명한다.
Hereinafter, the present invention will be described in more detail.

본 발명에서 유효성분으로 사용되는 무환자(sapindus mukurossi Gaertn)는 무환자과로 분류되며, 무환자 열매의 껍질에는 다량의 사포닌(saponin)이 함유되어 있기 때문에 예로부터 열매의 껍질을 비누 대용품으로 사용하였으며, 나무껍질을 거담제로 사용해 왔다. 최근에는 무환자의 다양한 효능이 보고되고 있으며, 특히 항균작용 및 리파아제 활성 억제작용이 보고되고 있다.The patient (sapindus mukurossi Gaertn) used as an active ingredient in the present invention is classified as a disease-free family, and since the bark of the fruitless fruit contains a large amount of saponin, the bark of the fruit has been used as a substitute for soap, bark Has been used as an expectorant. In recent years, various effects of patients have been reported, especially antimicrobial activity and lipase activity inhibitory activity has been reported.

본 발명의 무환자 추출물은 당업계의 통상적인 제조 방법에 따라 수득될 수 있으며, 구체적인 예를 들면 무환자 열매를 80% 에탄올 용액으로 추출 및 여과한 후, 여과액을 2~5일간 숙성 및 여과시키고 감압 상태에서 농축 및 건조하여 제조할 수 있다.The patient-free extract of the present invention can be obtained according to a conventional manufacturing method in the art, for example, after extracting and filtering the patient-free fruit with 80% ethanol solution, the filtrate is aged and filtered for 2 to 5 days and depressurized It can be prepared by concentrating and drying in a state.

본 발명의 무환자 추출물은 조성물 총 중량에 대하여 0.0001 내지 20중량%, 보다 바람직하게는 0.1 내지 5중량%로 함유된다. 이는 0.0001중량% 미만이면 그 효과가 미미하고, 20중량% 초과이면 구강 내 자극이 생길 수 있으며 그 효과 또한 오히려 떨어지기 때문에 바람직하지 않다. The patient-free extract of the present invention is contained in 0.0001 to 20% by weight, more preferably 0.1 to 5% by weight based on the total weight of the composition. If the amount is less than 0.0001% by weight, the effect is insignificant, and if it is more than 20% by weight, oral irritation may occur, and the effect is also deteriorated, which is not preferable.

본 발명의 구강용 조성물은 소르비톨액 및 카르복시메틸셀룰오로스나트륨을 더 함유할 수 있다. 소르비톨액 및 카르복시메틸셀룰로오스나트륨은 미세 기포를 형성하여 무환자 추출물을 구강 내 구석까지 전달하기 위해 사용된다.The composition for oral cavity of this invention may further contain sorbitol liquid and sodium carboxymethylcellulose. Sorbitol solution and sodium carboxymethylcellulose are used to form microbubbles and deliver the patient-free extract to the corner of the oral cavity.

본 발명의 소르비톨액은 조성물 총 중량에 대하여 30 내지 60중량%로 함유된다. 이는 30중량% 미만이면 기포가 조밀하지 않고, 60중량%를 초과하면 치약 제조가 용이하지 않기 때문에 바람직하지 않다.The sorbitol solution of the present invention is contained in 30 to 60% by weight based on the total weight of the composition. This is not preferable because bubbles are less dense if less than 30% by weight, and toothpaste production is not easy if more than 60% by weight.

본 발명의 카르복시메틸셀룰오로스나트륨은 조성물 총 중량에 대하여 1.0 내지 3.0 중량%로 함유된다. 이는 1.0중량% 미만이면 기포가 조밀하지 않고, 3.0중량%를 초과하면 치약제조가 용이하지 않기 때문에 바람직하지 않다.The carboxymethylcellulose sodium of the present invention is contained in 1.0 to 3.0% by weight based on the total weight of the composition. This is not preferable because bubbles are less dense if less than 1.0% by weight, and toothpaste is not easy to exceed 3.0% by weight.

본 발명에서 소르비톨액 및 카르복시메틸셀룰오로스나트륨에 의해 형성된 미세 기포는 0.0001~0.5mm, 가장 바람직하게는 0.1mm의 평균 기포 사이즈를 갖는다. 이는 0.0001mm 미만이면 자극을 유발할 가능성이 있고, 0.5mm 초과이면 유효성분을 치아 구석 전달하기 힘들기 때문에 바람직하지 않다.In the present invention, the fine bubbles formed by the sorbitol solution and the carboxymethyl cellulose sodium have an average bubble size of 0.0001 to 0.5 mm, most preferably 0.1 mm. This is not preferable because less than 0.0001mm may cause irritation, and if it is more than 0.5mm, it is difficult to deliver the active ingredient in the corner of the tooth.

본 발명의 구강용 조성물은 무환자 추출물, 소르비톨액 및 카르복시메틸셀룰로오스나트륨을 함유하여 잇몸질환 예방 및 구취 제거에 매우 효과적이다.The composition for oral cavity of the present invention contains a patient-free extract, sorbitol solution and sodium carboxymethyl cellulose are very effective in preventing gum disease and removing bad breath.

본 발명의 구강용 조성물은 그 제형에 있어서 특별히 한정되지 않으며, 구체적인 예를 들면, 치약, 구강용 세정제, 치아 미백제 등의 제형을 가질 수 있다.The composition for oral cavity of this invention is not specifically limited in the formulation, For example, it may have formulations, such as a toothpaste, a mouthwash, and a tooth whitening agent.

본 발명의 구강용 조성물은 제형 및 사용 목적에 따라 통상적으로 사용하는 연마제, 습윤제, 보조 기포제, 결합제, 감미제, pH 조절제, 방부제, 약효성분, 향료, 증백제, 색소, 용제 등을 함유할 수 있다. The composition for oral cavity of the present invention may contain abrasives, wetting agents, auxiliary foaming agents, binders, sweeteners, pH adjusting agents, preservatives, active ingredients, fragrances, brighteners, pigments, solvents and the like which are commonly used according to the formulation and purpose of use. .

이하, 실시예 및 비교예를 들어 본 발명을 보다 구체적으로 설명하지만 본 발명의 범위가 이에 제한되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the scope of the present invention is not limited thereto.

[제조예 1] 무환자 추출물의 제조Preparation Example 1 Preparation of Patient-Free Extract

무환자 나무의 열매를 80% 에탄올 용액으로 추출 및 여과한 후, 5일간 숙성하였다. 수득된 숙성물을 여과하여 불순물을 제거하고 감압 상태에서 농축 및 건조하여 무환자 추출물을 수득하였다.
The fruit of the patient tree was extracted with 80% ethanol solution and filtered, and then aged for 5 days. The obtained mature was filtered to remove impurities, concentrated and dried under reduced pressure to obtain a non-patient extract.

[실시예 1 및 비교예 1~5]Example 1 and Comparative Examples 1 to 5

하기 표 1의 조성으로 통상의 제조방법에 따라 실시예 1 및 비교예 1~5의 치약을 제조하였다(단위: 중량%). 상기 제조예 1에서 얻은 무환자 추출물을 이용하고, 소르비톨액(고형성분 70%, 액상 원료)은 ㈜ 백광산업에서 구입하여 사용하고, 카르복시메틸셀룰로오스나트륨은 허큘리스(HERCULES)사로부터 구입하여 사용하였다.
Toothpaste of Example 1 and Comparative Examples 1 to 5 was prepared according to a conventional manufacturing method in the composition of Table 1 below (unit: wt%). Using the non-patient extract obtained in Preparation Example 1, the sorbitol solution (70% solid component, liquid raw material) was purchased from Baekwang Industrial Co., Ltd., and sodium carboxymethylcellulose was purchased from Hercules.

성분명Ingredients 실시예 1Example 1 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 비교예 4Comparative Example 4 비교예 5Comparative Example 5 불화나트륨Sodium fluoride 0.300.30 0.300.30 0.300.30 0.300.30 0.300.30 0.300.30 실리카Silica 17.017.0 17.017.0 17.017.0 17.017.0 17.017.0 17.017.0 무환자추출물Patient-free extract 1.01.0 -- -- 1.01.0 20.020.0 30.030.0 소르비톨액Sorbitol solution 50.050.0 50.050.0 25.025.0 25.025.0 25.025.0 25.025.0 카르복시메틸셀룰로오스나트륨Carboxymethyl Cellulose Sodium 2.02.0 2.02.0 0.70.7 0.70.7 0.70.7 0.70.7 삭카린나트륨Zaccarin Sodium 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 파라옥시안식향산메틸Methyl paraoxybenzoate 0.20.2 0.20.2 0.20.2 0.20.2 0.20.2 0.20.2 향료Spices 1.01.0 1.01.0 1.01.0 1.01.0 1.01.0 1.01.0 라우릴황산나트륨Sodium Lauryl Sulfate 2.02.0 2.02.0 2.02.0 2.02.0 2.02.0 2.02.0 정제수Purified water To 100To 100 To 100To 100 To 100To 100 To 100To 100 To 100To 100 To 100To 100

[시험예 1] 기포 사이즈 비교Test Example 1 Bubble Size Comparison

상기 실시예 1 및 비교예 1~3의 치약을 각각 3.5g씩 취한 후 브러싱 머신 (Brushing machine, 주문 제작)으로 30분간 브러시하였다. 발생된 기포를 슬라이드 글라스(slide glass)에 올린 후, 커버글라스로 덮고 광학현미경 (올림푸스 DP70, 4배 렌즈 사용)을 사용하여 평균적인 기포 사이즈를 측정하였다. 측정된 기포 사이즈는 하기 표 2에 나타내었다.Each toothpaste of Example 1 and Comparative Examples 1 to 3 was taken 3.5g and then brushed with a brushing machine (custom) for 30 minutes. The generated bubbles were placed on a slide glass, covered with a cover glass, and the average bubble size was measured using an optical microscope (Olympus DP70, using 4x lens). The measured bubble sizes are shown in Table 2 below.

구분division 실시예 1Example 1 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 평균 기포 사이즈(지름, mm)Average bubble size (diameter, mm) 0.10.1 0.10.1 1.11.1 1.01.0

상기 표 2의 결과로부터 알 수 있듯이, 카르복시메틸셀룰로오스나트륨 및 소르비톨액을 바람직한 함량 범위로 함유하는 실시예1 및 비교예1은 평균 0.1mm의 미세한 기포를 생성하였으나, 카르복시메틸셀룰로오스나트륨 및 소르비톨액을 바람직한 함량 범위 밖으로 함유하는 비교예 2~3은 지름 1.0mm 이상의 기포를 생성하는 것을 확인할 수 있었다.
As can be seen from the results of Table 2, Example 1 and Comparative Example 1 containing a carboxymethyl cellulose sodium and sorbitol liquid in a preferred content range produced a fine bubble of 0.1mm on average, but the carboxymethyl cellulose sodium and sorbitol liquid It was confirmed that Comparative Examples 2 to 3 containing out of the preferred content range produces bubbles having a diameter of 1.0 mm or more.

[시험예 2] 타액 내의 세균수 측정 Test Example 2 Measurement of the Number of Bacteria in Saliva

실험대상자 60명에게 6시간 동안 일체의 구강환경관리를 중지시킨 후 아래의 방법으로 타액 내 세균 수를 측정하였다. 이후 타액 내 세균 평균수치가 비슷하도록 6군으로 나누었다. 각각의 군에 대하여 실험에 영향을 미칠 수 잇는 구강진료수취를 금하고 2주간 실시예 1와 비교예 1~5의 시험 양치액으로 양치하게 하였다. 2주 후 6시간 동안 일체의 구강환경관리를 중지시킨 후 다시 타액 내 세균 수를 측정하였다Sixty six subjects were suspended from oral environment management for 6 hours, and then the number of bacteria in saliva was measured by the following method. Since the average saliva bacteria in saliva was divided into six groups. For each group, oral treatment that could affect the experiment was forbidden, and it was allowed to brush with the test nutrient solution of Example 1 and Comparative Examples 1 to 5 for 2 weeks. After 2 weeks, all oral environmental management was stopped for 6 hours, and again the number of bacteria in saliva was measured.

<타액 내의 세균 수 측정 방법><Method of Measuring Bacteria in Saliva>

15㎖ 팔콘 튜브(Falcon tube)에 멸균된 0.1% 펩톤용액(0.9% NaCl 1000㎖ 에 펩톤(peptone) 1g을 첨가)을 5㎖씩 분주하여 60개를 준비한 후, 실험 대상자 60명에게 펩톤용액을 15초간 수구하게 한 후, 이 펩톤용액을 멸균된 0.067M 포스페이트 버퍼(Phosphate buffer) 용액(pH 7.2)으로 10배 희석하였다. 희석한 이 용액의 100㎕를 취하여 바시트라신(bacitracin) 및 발리노마이신(valinomycin) 항생제가 포함된 미티스 살리바리우스(Mitis Salivarius) 배지(Agar)에 분주하고, 멸균된 벤딩 유리(bending glass)로 평판에 전체적으로 도말한 다음, 37℃ 배양기에 12시간 배양 후, 혐기성 챔버(Anaerobic chamber)에서 37℃ 48시간 동안 다시 배양한 다음, 콜로니 카운터(Colony counter)를 이용해 각 배지에서 스트렙토코커스 무탄스(Streptococcus mutans)의 콜로니(colony)를 측정하여 기록하였다. 스트렙토코커스 무탄스의 콜로니는 현미경적 검사를 통하여 균의 종류를 확인하고, 표준균주 스트렙토코커스 무탄스 NTCC 10449를 MSA에 같은 시간과 조건으로 배양한 후 콜로니의 형태를 확인하여, 실험대상자에서 스트렙토코커스 무탄스의 콜로니만을 선별하여 측정하였다. 실험 대상자 한사람 당, 희석된 펩톤수구액을 바시트라신 및 발리노마이신 항생제가 포함된 미티스 살리바리우스 배지 평판 2개에 분주하여, 콜로니 측정을 1차, 2차의 2회에 걸쳐 시행하여 두 측정의 평균값을 실험대상자의 스트렙토코커스 무탄스의 수로 하였다. 측정한 결과는 하기 표 3에 나타내었다. 60 ml of 5% aliquots of sterile 0.1% peptone solution (1 g of peptone was added to 1000 ml of 0.9% NaCl) were prepared in a 15 ml Falcon tube, and 60 peptone solutions were prepared. After 15 seconds of hydration, the peptone solution was diluted 10-fold with sterile 0.067 M Phosphate buffer solution (pH 7.2). 100 μl of this diluted solution is taken and dispensed into Mitis Salivarius medium (Agar) containing bacitracin and valinomycin antibiotics, and sterilized bending glass. The plate was plated as a whole, incubated for 12 hours in a 37 ° C. incubator, and then incubated for 48 hours at 37 ° C. in an anaerobic chamber. Then, the Streptococcus mutans (Colony counter) Colonies of Streptococcus mutans) were measured and recorded. The microorganisms of Streptococcus mutans colonies were identified by microscopic examination. After incubating the standard strain Streptococcus mutans NTCC 10449 in MSA at the same time and conditions, the colonies were identified. Only non-tans colonies were selected and measured. For each test subject, diluted peptone poloxes were dispensed into two plates of Mytis salivarius medium containing bacitracin and valinomycin antibiotics, and colony measurements were performed in two rounds of primary and secondary. The average value of the measurement was taken as the number of Streptococcus mutans of the subject. The measured results are shown in Table 3 below.

경과 시간Elapsed time 실시예 1Example 1 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 비교예 4Comparative Example 4 비교예 5Comparative Example 5 실험 직후Right after the experiment 110110 108108 108108 109109 109109 112112 2주 후after 2 weeks 1313 9090 9898 5353 4949 6060

상기 표 3의 결과로부터 알 수 있듯이, 무환자 추출물을 함유하지 않은 비교예 1~2의 조성물은 스트렙토코커스 무탄스의 수가 거의 줄어들지 않은 반면, 무환자 추출물을 1, 20, 30중량%로 함유한 비교예 3~5 는 비교예 1~2와 비교해 세균 수치가 감소하였다. 그러나 무환자 추출물을 1중량% 함유하며 동시에 미세 기포를 발생하는 실시예 1이 미세 기포를 발생하지 못하는 비교예 3~5와 비교하여 가장 탁월한 항균효과를 나타내었다.As can be seen from the results of Table 3, the composition of Comparative Examples 1 to 2 containing no patient extract, while the number of Streptococcus mutans hardly decreased, the comparative example containing 1, 20, 30% by weight of patient-free extract As for 3-5, bacteria level decreased compared with Comparative Examples 1-2. However, Example 1 containing the non-patient extract and at the same time generating microbubbles showed the most excellent antimicrobial effect as compared to Comparative Examples 3 to 5 that do not generate microbubbles.

이를 통하여, 미세기포가 무환자 추출물을 치아 구석 미세한 부분까지 잘 전달해 주어 항균효과를 극대화시켜 세균 수를 매우 크게 감소시키는 것을 확인하였다.
Through this, it was confirmed that the microbubble well-delivered the patient-free extract to the minute corners of the teeth to maximize the antibacterial effect to significantly reduce the number of bacteria.

[시험예 3] 구취 제거 효과 측정Test Example 3 Measurement of Bad Breath Removal Effect

실험대상자 120명에게 48시간 동안 일체의 구강환경관리를 중지시킨 후 할리메타로 구취 정도를 측정한 다음 평균수치가 비슷하도록 6군으로 나누었다. 각각의 군에 대하여 실시예 1와 비교예 1~5의 시험 양치액으로 양치하게 하였다. 양치 후 30분 경과시점에 다시 구취 정도를 측정하였다. 이어서 28일간 각각의 시험 양치액을 1일 2회씩 사용하도록 하였다. 7일, 14일, 21일 및 28일이 경과한 때에 소환하여, 양치 후 30분 경과시점에 다시 구취 정도를 측정하였으며, 치약 조성물의 사용기간에 따른 구취 정도는 하기 표 4에 나타내었다.120 subjects were suspended for 48 hours after oral administration of all oral environment, and the degree of bad breath was measured using a harimeta. Each group was made to brush with the test fern of Example 1 and Comparative Examples 1-5. At 30 minutes after brushing, the degree of bad breath was measured again. Each test fern was then used twice a day for 28 days. After 7 days, 14 days, 21 days and 28 days elapsed, the degree of bad breath was measured again 30 minutes after brushing the teeth, and the degree of bad breath according to the use period of the toothpaste composition is shown in Table 4 below.

사용 기간Period of use 실시예 1Example 1 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 비교예 4Comparative Example 4 비교예 5Comparative Example 5 30분30 minutes 215215 219219 223223 220220 220220 220220 7일7 days 130130 217217 222222 170170 150150 180180 14일14 days 105105 215215 217217 145145 130130 160160 21일21st 8686 212212 219219 115115 103103 140140 28일28 days 6262 209209 217217 102102 9696 131131

상기 표 4의 결과를 보면, 무환자 추출물을 사용하지 않은 비교예 1~2의 구강 조성물의 구취 점수는 거의 변화가 없는 반면, 무환자 추출물을 1, 20, 30중량%로 함유한 비교예 3~5 는 비교예 1~2와 비교하여 구취 점수는 어느 정도 감소되었다. 그러나 무환자 추출물을 1중량% 함유하며 동시에 미세 기포를 발생하는 실시예 1이 미세 기포를 발생하지 못하는 비교예 3~5와 비교하여 가장 탁월한 구취 제거 효과를 나타내었다.Looking at the results of Table 4, while the bad breath score of the oral composition of Comparative Examples 1 to 2 without using the patient-free extract is almost unchanged, Comparative Examples 3 to 5 containing the patient-free extract 1, 20, 30% by weight Compared with Comparative Examples 1 and 2, the bad breath score was somewhat reduced. However, Example 1 containing 1% by weight of the patient-free extract and at the same time generating microbubbles exhibited the most excellent bad breath removing effect compared to Comparative Examples 3 to 5 which do not generate microbubbles.

이를 통하여, 미세기포가 무환자 추출물을 치아 구석 미세한 부분까지 잘 전달해 주어 구취 제거 효과를 극대화시키는 것을 확인하였다.
Through this, it was confirmed that the microbubble delivers the patient-free extract well to the minute corners of the teeth to maximize the bad breath removal effect.

[시험예 4] 잇몸질환 예방효과 측정[Test Example 4] Measurement of gum disease prevention effect

잇몸질환 예방효과를 확인하기 위해서 치은 지수를 측정하였으며, 그 방법은 다음과 같다. 먼저, 피검자 80명을 선별한 후 실험기간 동안 항생제의 복용과 실험에 영향을 미칠 수 있는 구강진료수취를 금하였다. 실시예 1 및 비교예 1~3 각각에 피검자를 20명씩 나누고 치은염 지수를 Talbott, Mandel and Chilton이 변형한 Loe의 치은염 평점 기준에 따라 측정하였다.To determine the effect of preventing gum disease, the gingival index was measured and the method was as follows. First of all, 80 subjects were screened and oral administration was prohibited during the experimental period. 20 subjects were divided into Example 1 and Comparative Examples 1 to 3, and the gingivitis index was measured according to the gingivitis grading criteria of Loe modified by Talbott, Mandel and Chilton.

<Talbott, Mandel and Chilton이 변형한 Loe의 치은염 지수>Loe's Gingivitis Index Modified by Talbott, Mandel and Chilton

Loe의 치은염평점기준Loe's Gingivitis Score Standard

0: 염증 없음0: no inflammation

1: 경미 치은염(색조의 약한 변화 및 약한 부종) - 치주낭심측정시 출혈 없음1: Mild gingivitis (weak change of color and weak edema)-no bleeding during periodontal cyst measurement

2: 중등 치은염(발적, 부종) - 치주낭심측정시 출혈2: moderate gingivitis (redness, edema)-bleeding during periodontal cystic measurement

3: 고도 치은염(궤양) - 저절로 출혈되는 경향3: highly gingivitis (ulcer)-tendency to bleed on its own

경과 시간Elapsed time 실시예 1Example 1 비교예 1Comparative Example 1 비교예 2Comparative Example 2 비교예 3Comparative Example 3 초기치Initial value 1.61±0.211.61 ± 0.21 1.60±0.211.60 ± 0.21 1.60±0.211.60 ± 0.21 1.58±0.211.58 ± 0.21 2주2 weeks 1.26±0.141.26 ± 0.14 1.59±0.241.59 ± 0.24 1.60±0.251.60 ± 0.25 1.42±0.221.42 ± 0.22 4주4 weeks 1.07±0.161.07 ± 0.16 1.58±0.201.58 ± 0.20 1.58±0.221.58 ± 0.22 1.25±0.181.25 ± 0.18 개선 지수Improvement index 0.54±0.180.54 ± 0.18 0.02±0.220.02 ± 0.22 0.02±0.230.02 ± 0.23 0.33±0.200.33 ± 0.20

상기 표 5의 결과를 보면, 무환자 추출물을 함유하지 않은 비교예 1~2는 치은염 완화 효과가 거의 없는 반면, 무환자 추출물을 1중량%로 함유하는 비교예 3은 어느 정도 치은염 완화 효과를 나타내었다. 그러나 무환자 추출물을 1중량% 함유하면서 미세 기포를 발생하는 실시예 1의 경우 미세 기포를 발생하지 못하는 비교예 3과 비교하여 탁월한 치은염 개선 효과를 나타내었다. Looking at the results of Table 5, Comparative Examples 1 and 2 containing no patient extract had almost no gingivitis alleviating effect, while Comparative Example 3 containing 1% by weight of no patient extract showed some degree of gingivitis alleviating effect. However, in the case of Example 1 containing 1% by weight of the patient-free extract to generate microbubbles showed an excellent gingivitis improvement effect compared to Comparative Example 3 that does not generate microbubbles.

이를 통하여, 미세기포가 무환자 추출물을 치아 구석 미세한 부분까지 잘 전달해 주어 치은염과 같은 잇몸 질환을 효과적으로 예방 및 개선하는 것을 확인하였다.Through this, it was confirmed that the microbubble effectively delivers the patient-free extract to the minute corners of the teeth, effectively preventing and improving gum disease such as gingivitis.

Claims (7)

무환자(sapindus mukurossi Gaertn) 추출물을 유효성분으로 함유하는 구강용 조성물.Oral patient (sapindus mukurossi Gaertn) composition containing an extract as an active ingredient. 제 1항에 있어서, 상기 무환자 추출물은 조성물 총 중량에 대하여 0.0001 내지 20중량%로 함유되는 것을 특징으로 하는 구강용 조성물.The composition for oral cavity of claim 1, wherein the patient-free extract is contained in an amount of 0.0001 to 20% by weight based on the total weight of the composition. 제 1항에 있어서, 상기 조성물이 소르비톨액 및 카르복시메틸셀룰로오스나트륨을 더 함유하는 것을 특징으로 하는 구강용 조성물.The oral composition according to claim 1, wherein the composition further contains a sorbitol solution and sodium carboxymethylcellulose. 제 3항에 있어서, 상기 소르비톨액 및 카르복시메틸셀룰로오스나트륨은 0.0001~0.5mm의 평균 기포 사이즈를 갖는 미세 기포를 발생시키는 것을 특징으로 하는 구강용 조성물.4. The composition for oral cavity according to claim 3, wherein the sorbitol solution and sodium carboxymethylcellulose generate fine bubbles having an average bubble size of 0.0001 to 0.5 mm. 제 3항에 있어서, 상기 소르비톨액은 조성물 총 중량에 대하여 30 내지 60 중량%로 함유되는 것을 특징으로 하는 구강용 조성물.4. The composition for oral cavity of claim 3, wherein the sorbitol solution is contained in an amount of 30 to 60 wt% based on the total weight of the composition. 제 3항에 있어서, 상기 카르복시메틸셀룰로오스나트륨이 조성물 총 중량에 대하여 1.0 내지 3.0중량%로 함유되는 것을 특징으로 하는 구강용 조성물.4. The composition for oral cavity of claim 3, wherein the carboxymethylcellulose sodium is contained in an amount of 1.0 to 3.0% by weight based on the total weight of the composition. 제 1항 내지 제 6항 중 어느 한 항에 있어서, 상기 조성물이 잇몸 질환 예방 및 구취 제거를 위한 것임을 특징으로 하는 구강용 조성물.The composition for oral cavity according to any one of claims 1 to 6, wherein the composition is for preventing gum disease and removing bad breath.
KR1020100115608A 2010-11-19 2010-11-19 Oral composition containing extract of sapindus mukurossi Gaertn KR101756306B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020100115608A KR101756306B1 (en) 2010-11-19 2010-11-19 Oral composition containing extract of sapindus mukurossi Gaertn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100115608A KR101756306B1 (en) 2010-11-19 2010-11-19 Oral composition containing extract of sapindus mukurossi Gaertn

Publications (2)

Publication Number Publication Date
KR20120054297A true KR20120054297A (en) 2012-05-30
KR101756306B1 KR101756306B1 (en) 2017-07-12

Family

ID=46270188

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100115608A KR101756306B1 (en) 2010-11-19 2010-11-19 Oral composition containing extract of sapindus mukurossi Gaertn

Country Status (1)

Country Link
KR (1) KR101756306B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104983612A (en) * 2015-06-18 2015-10-21 广州无患子生物科技有限公司 Plant tooth health care product and preparing method thereof
KR20180113255A (en) * 2017-04-06 2018-10-16 주식회사 웰빙라이프 Herbal preservative composition for wet tissue
KR102235138B1 (en) * 2020-09-01 2021-04-02 두리화장품 주식회사 Cleaning composition containing subcritical natural extract

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104983612A (en) * 2015-06-18 2015-10-21 广州无患子生物科技有限公司 Plant tooth health care product and preparing method thereof
KR20180113255A (en) * 2017-04-06 2018-10-16 주식회사 웰빙라이프 Herbal preservative composition for wet tissue
KR102235138B1 (en) * 2020-09-01 2021-04-02 두리화장품 주식회사 Cleaning composition containing subcritical natural extract

Also Published As

Publication number Publication date
KR101756306B1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
KR101723588B1 (en) Composition for mouth comprising camellia japonica l leaf extract and manufacturing method thereof
KR20000016351A (en) Antimicrobial agents for oral hygiene products
CN107595750A (en) A kind of active inflammation-diminishing toothpaste
CN107468553A (en) A kind of anti-caries toothpaste
KR101756306B1 (en) Oral composition containing extract of sapindus mukurossi Gaertn
KR101480690B1 (en) Oral composition containing natural agent
KR102207872B1 (en) Oral composition for preventation or treatment of oral disease
KR20160041408A (en) Oral composition containing fermentative extract of galla rhoids as active ingredient
KR101068210B1 (en) The mixtures of extracts of Dryopteris crassirhizoma, pine needles and pomegranate for the inhibition of dental caries and periodontal diseases
CN115337218B (en) Oral care composition, application thereof, toothpaste, mouthwash and oral gel containing same
KR102337982B1 (en) Toothpaste composition containing hemp seed oil as an active ingredient
KR20130081243A (en) Composition comprising tauroursodeoxycholic acid
CN110623911A (en) Whitening toothpaste composition capable of effectively inhibiting growth of dental plaque and preparation method thereof
JP2019196329A (en) Periodontal disease prevention oral composition
Kim et al. Antimicrobial effect of commercially available mouth rinsing solutions and natural herbal extracts on Streptococcus mutans
Ghelichli Formulation of new herbal Salvadora toothpaste with antidecay, wound healing and caring tooth and Periodontal diseases
KR101021787B1 (en) Oral composition having effects on periodontal disease and removing halitosis
KR101910716B1 (en) Mouthwash containing green tea
KR20170037230A (en) Oral composition comprising cassava extract
KR102343906B1 (en) Oral composition comprising sericin
JP2014043441A (en) Composition for oral cavity and candida biofilm formation inhibitor
CN114588057B (en) Fresh and whitening toothpaste and preparation process thereof
KR102338682B1 (en) Oral cleansing composition
CN107362112A (en) One kind shield gum healing toothpaste
KR20160068709A (en) Composition for toothpaste comprising cypress extract and manufacturing method thereof

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant